Sobi Names Kevin Springman Vice President, Franchise Head in North America

WALTHAM, Mass.–(BUSINESS WIRE)–Sobi, an international biopharmaceutical company dedicated to rare
diseases, announced today that Kevin Springman has joined the company as
the Vice President, Franchise Head of Synagis® (palivizumab)
in North America.

Springman has over 22 years of pharmaceutical and biotech experience
spanning sales, marketing, market access, strategic project management
and patient services. He spent two decades at AstraZeneca, most recently
serving as Franchise Head of Infectious Disease. He previously served as
a Senior Director of Strategic Products, and prior to that advanced
through multiple sales, marketing and other commercial positions. Kevin
received his bachelor’s degree from St. Joseph’s University and
completed a post-graduate program at Fork Union Military Academy.

“With the completion of Sobi’s acquisition of rights to Synagis in the
U.S., Sobi in North America was pleased to welcome the Synagis sales and
marketing team, including Kevin as the franchise head, to our North
American team. This acquisition nearly tripled the size of our
organization, establishing a critical scale to drive sustainable growth
in the U.S. Additionally, Kevin’s deep understanding of Synagis
specifically and of strategic sales and marketing generally will make
him a valuable addition to our leadership team,” said Rami Levin,
President of Sobi in North America.

“I have had the privilege of helping deliver Synagis not only to
physicians and hospitals but also the patients that need it for several
years, and I am grateful to now have the opportunity to help Sobi
continue this important work,” said Springman.

About Sobi in North America
As the North American affiliate
of international biopharmaceutical company Sobi™, our team is committed
to Sobi’s vision of providing access to innovative treatments that make
a significant difference in the lives of individuals with rare diseases.
Our product portfolio includes multiple approved treatments, focused on
immunology and genetics/metabolism. With North American headquarters in
the Boston area, Canadian headquarters in the Toronto area, and field
sales, medical and market access representatives spanning North America,
our growing team has a proven track record of commercial excellence.
More information is available at
For more information about Sobi, visit


Trista Morrison

error: Content is protected !!